iiinova — where your digital self keeps evolving

Matteo Cereda

@matteocereda.bsky.social

414 followers 119 following 0 posts

M.Eng., Ph.D. | RNA oncology | Associate Professor @ University of Milan | Group leader | Proudly @Ceredalab

Posts Replies Media

Reposted by Matteo Cereda

Cereda Lab @ceredalab.bsky.social · 05/12/2025

📢 How does #epigenetics fuel #chromosome #instability in #cancer? Together with @IlioVitale and @deadoc80.bsky.social, we highlighted two recent papers from @NatGen and @CD_AACR in our newly published @cp-trendscancer.bsky.social Spotlight! Check it out here 👉 www.sciencedirect.com/science/arti...

1106

Reposted by Matteo Cereda

Danny IncaRNAto @incarnatolab.bsky.social · 15/11/2024

Fellow #RNA lovers, please repost 🙏: 2 ERC-funded Post-doc positions are available in our lab to investigate #RNA structural ensemble and their dynamics in living cells. Application link: t.co/pYJ3H3j705

t.co

https://www.rug.nl/about-ug/work-with-us/job-opportunities/?details=00347-02S000B06P

03549

Reposted by Matteo Cereda

Cereda Lab @ceredalab.bsky.social · 18/11/2024

🚨 Thrilled to share also here this exciting and collaborative research on #KRAS G12C adaptive resistance and therapy recently out in @NatureComms W/ @AmbrogioLab @SantamariaLab @BiagioRicciutiMD ➡️ www.nature.com/articles/s41... @oncoalert.bsky.social l @natureportfolio.bsky.social

nature.com

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade - Nature Communications

KRAS G12C mutant selective inhibitors targeting inactive state have been approved for use in non-small cell lung cancer (NSCLC). Here, using models derived from a patient with NSCLC who progressed on ...

0205

Reposted by Matteo Cereda

Cereda Lab @ceredalab.bsky.social · 17/11/2024

Among so many amazing starter packs, but none focused on RNA splicing - so we made one! Check out the accounts we’ve included so far, and let us know if you’d like to be added or have suggestions! go.bsky.app/TigRnmC #rnasplicing

131612